CASPALLO: Allodepleted T Cells Transduced With Inducible Caspase 9 Suicide Gene

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

December 31, 2008

Primary Completion Date

November 30, 2011

Study Completion Date

July 31, 2026

Conditions
Acute Lymphoblastic LeukemiaNon-Hodgkin's LymphomaMyelodysplastic SyndromeChronic Myeloid Leukemia
Interventions
BIOLOGICAL

Allodepleted T Cells

"Dose Level 1 = 1 x 10e6 T cells/kg; Dose Level 2 = 3 x 10e6 T cells/kg; Dose Level 3 = 1 x 10e7 T cells/kg.~Patients may be enrolled at the next dose level of T cells when all patients at the previous dose level have reached Day 42 post-T cell infusion without unacceptable toxicity."

Trial Locations (2)

77030

Texas Children's Hospital, Houston

The Methodist Hospital, Houston

All Listed Sponsors
collaborator

The Methodist Hospital Research Institute

OTHER

collaborator

Center for Cell and Gene Therapy, Baylor College of Medicine

OTHER

lead

Baylor College of Medicine

OTHER

NCT00710892 - CASPALLO: Allodepleted T Cells Transduced With Inducible Caspase 9 Suicide Gene | Biotech Hunter | Biotech Hunter